|
|
| LECTURES
|
| Monday,
May 12, 2003 |
| Time |
Title |
Speaker |
|
 |
|
8:00
- 9:30 |
Plenary
Session #1 |
|
| 8:00
- 8:05 |
Laboratory
Science: Overviews and Opportunities |
William
L. Carroll, M.D. |
|
| 8:05
- 8:20 |
Gene
profiling in ALL |
Cheryl
Willman, M.D. |
|
| |
Question
& Answer |
|
|
| 8:20
- 8:35 |
The
New Genetics of T-Cell ALL: A Fish Tale
|
A.
Thomas Look, M.D. |
|
| |
Question
& Answer |
|
|
| 8:35
- 8:50 |
Apoptosis
MDR in ALL: Significance and Exploitation
|
Michael
Andreeff, M.D., Ph.D. |
|
| |
Question
& Answer |
|
|
| 8:50
- 9:05 |
Pharmacogenomics
|
Mary
Relling, Pharm.D. |
|
| |
Question
& Answer |
|
|
| 9:05
- 9:20 |
Minimal
residual disease in ALL – Methods and Significance |
Wendy Stock, M.D.
Jerry Radich, M.D. |
|
| 9:20
- 9:35 |
Preclinical Models
and New Agent Evaluation |
John
Yu, M.D., Ph.D. |
|
|
|
9:50
- 11:30 |
Plenary
Session #2 |
| |
| 9:50 |
Clinical
Science/New Directions for Trials |
Hagop
M. Kantarjian, M.D. |
|
| 9:55
- 10:05 |
COG
Classification for Risk-Adapted Therapy |
Kirk
Schultz, M.D. |
|
| |
Question
& Answer |
|
|
| 10:05
- 10:20 |
Treatment
of Ph+ ALL |
Deborah
Thomas, M.D. |
|
| 10:20
- 10:35 |
Allogeneic
and autologous SCT |
|
|
| |
|
Stephen
J. Forman, M.D. |
|
| |
|
Jacob
M. Rowe, M.D. |
|
| |
|
Anthony
Goldstone, M.R.C.P. |
|
| |
|
Charles
Linker, M.D. |
|
| |
|
Stephen
J. Forman, M.D. |
|
| 10:35
– 10:50 |
Treatment
of Burkitt ALL |
Mitchell
S. Cairo, M.D. |
|
| |
Question
& Answer |
|
|
| 10:50
– 11:05 |
Treatment
of T-cell ALL |
Barbara
Asselin, M.D. |
|
| |
Question
& Answer |
|
|
| 11:05
– 11:20 |
Adolescent
ALL
|
Sima
Jeha, M.D. |
|
| |
Question
& Answer |
|
|
| |
|
4:00
- 5:00 |
Final
Plenary Session |
|
|
| |
Working
Group A: Minimal Residual Disease |
Michael
Borowitz, M.D., Ph.D.
Wendy Stock, M.D. |
|
| |
Working
Group B: Immunotherapeutic Approaches: Antibodies and Vaccines
|
Deborah
Thomas, M.D.
John Leonard, M.D. |
|
| |
Working
Group C: Stem Cell Transplantation |
Frederick
R. Applebaum, M.D.
Stella M. Davies, Ph.D. |
|
| |
Working
Group D: Ph+ ALL |
Marty
Tallman, M.D.
Bruce Camitta, M.D. |
|
| |
Working
Group E: New Agents and Drug Resistance |
Mary
Relling, Pharm.D.
Hagop Kantarjian, M.D. |
|
| |
Working
Group F: Adolescent ALL |
James
Nachman, M.D.
Richard A. Larson, M.D. |
|
|
|
